Drug profile

The FDA adverse-event record for Glargine Insulin

18 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Glargine Insulin. See the species affected, top reactions, and outcomes below.

18
adverse-event reports
33.3%
death-coded share
Cat
most-reported species
6
Death by euthanasia - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
18
Total Reports
6
Deaths Reported
33.3%
Death Rate

Active Ingredients

Glargine Insulin

Administration Routes

SubcutaneousUnknownOral

Species Affected

Cat 15
Dog 2
Human 1

Most Affected Breeds

Domestic Shorthair 7
Domestic Longhair 2
Himalayan 2
Ragdoll 1
Retriever - Golden 1
Unknown 1
Cat (other) 1
Domestic Mediumhair 1
Shepherd Dog - German 1
Siamese 1

Most Reported Reactions

Death by euthanasia 6
Decreased appetite 4
Hyperglycaemia 4
Anorexia 2
Weight loss 2
Hypernatremia 2
Hypoglycaemia 2
Drug prescribing error 2
Lethargy (see also Central nervous system depression in Neurological) 2
Localised hair loss 2
Ketonuria 2
Elevated blood urea nitrogen (BUN) 2

Outcome Breakdown

Ongoing
7 (38.9%)
Euthanized
6 (33.3%)
Outcome Unknown
3 (16.7%)
Recovered/Normal
1 (5.6%)
Recovered with Sequela
1 (5.6%)

Glargine Insulin Adverse Event Insights

18 reports name Glargine Insulin; 6 recorded a death outcome (33.3% of reported events, not a population-level mortality rate). Active ingredient: Glargine Insulin. Administration routes: Subcutaneous, Unknown, Oral.

By species: Cat (15 reports), Dog (2 reports), Human (1 reports). By breed: Domestic Shorthair (7), Domestic Longhair (2), Himalayan (2).

Leading clinical signs: Death by euthanasia (6), Decreased appetite (4), Hyperglycaemia (4), Anorexia (2). Outcome, 18 coded reports: Ongoing leads at 38.9%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.